Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AHGNYSEAMERICAN:CTMNASDAQ:EGHTNASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAHGAkso Health Group$1.26+2.0%$1.45$0.71▼$2.35$182.88M-0.6869,053 shs2,581 shsCTMCastellum$1.06$1.05$0.12▼$2.83$91.20M-10.113.89 million shs1.55 million shsEGHT8X8$1.86$1.76$1.51▼$3.52$250.13M1.791.09 million shs3.78 million shsOABIOmniAb$1.70+0.6%$1.58$1.22▼$4.96$207.64M-0.02652,329 shs1.85 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAHGAkso Health Group0.00%-2.71%-14.63%+3.72%+53.14%CTMCastellum0.00%+2.91%+7.11%0.00%+469.89%EGHT8X80.00%+6.29%+14.46%-7.00%-16.22%OABIOmniAb0.00%+6.92%+33.86%-29.17%-54.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAHGAkso Health Group0.8851 of 5 stars0.05.00.00.03.30.00.0CTMCastellum2.8765 of 5 stars3.53.00.00.03.32.50.0EGHT8X84.0136 of 5 stars4.04.00.00.02.02.51.9OABIOmniAb3.096 of 5 stars3.51.00.00.02.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAHGAkso Health Group 0.00N/AN/AN/ACTMCastellum 3.00Buy$3.00183.02% UpsideEGHT8X8 2.00Hold$2.5135.18% UpsideOABIOmniAb 3.00Buy$7.00311.76% UpsideCurrent Analyst Ratings BreakdownLatest CTM, EGHT, OABI, and AHG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/20/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.70 ➝ $2.705/14/2025EGHT8X8B. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $3.005/12/2025OABIOmniAbBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.005/10/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025CTMCastellumMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy$3.004/24/2025CTMCastellumMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.30 ➝ $2.70(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAHGAkso Health Group$2.41M75.88N/AN/A$0.95 per share1.32CTMCastellum$44.76M2.04N/AN/A$0.29 per share3.66EGHT8X8$715.07M0.35$0.65 per share2.84$0.93 per share2.00OABIOmniAb$26.39M7.87N/AN/A$2.37 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAHGAkso Health Group-$9.46MN/A0.00∞N/AN/AN/AN/AN/ACTMCastellum-$9.98M-$0.17N/A∞N/A-15.61%-40.01%-20.51%7/15/2025 (Estimated)EGHT8X8-$27.21M-$0.21N/A18.60N/A-3.81%5.73%0.90%N/AOABIOmniAb-$62.03M-$0.58N/AN/AN/A-229.11%-21.37%-18.84%8/6/2025 (Estimated)Latest CTM, EGHT, OABI, and AHG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025OABIOmniAb-$0.17-$0.17N/A-$0.17$4.49 million$4.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAHGAkso Health GroupN/AN/AN/AN/AN/ACTMCastellumN/AN/AN/AN/AN/AEGHT8X8N/AN/AN/AN/AN/AOABIOmniAbN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAHGAkso Health GroupN/A8.198.18CTMCastellum0.252.922.92EGHT8X82.771.201.20OABIOmniAbN/A4.704.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAHGAkso Health Group1.21%CTMCastellum3.39%EGHT8X893.99%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipAHGAkso Health GroupN/ACTMCastellum29.79%EGHT8X82.01%OABIOmniAb8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAHGAkso Health Group40145.72 millionN/ANot OptionableCTMCastellum20786.04 million60.41 millionNot OptionableEGHT8X81,942134.48 million131.78 millionOptionableOABIOmniAb7122.14 million111.63 millionOptionableCTM, EGHT, OABI, and AHG HeadlinesRecent News About These CompaniesOmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLCJune 17, 2025 | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) Short Interest Down 15.8% in MayJune 3, 2025 | marketbeat.comChairman of OmniAb Picks Up 3.0% More StockMay 19, 2025 | uk.finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Director Steven Love Purchases 25,000 SharesMay 15, 2025 | insidertrades.comInsider Buying: OmniAb, Inc. (NASDAQ:OABI) Director Buys 65,000 Shares of StockMay 14, 2025 | insidertrades.comOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston SummitMay 13, 2025 | businesswire.comIs OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comOmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOmniAb, Inc. (OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comOmniAb Introduces the xPloration® Partner Access ProgramMay 9, 2025 | tmcnet.comOmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comOmniAb Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comVERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid TumorsMay 5, 2025 | quiverquant.comQVERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramMay 5, 2025 | globenewswire.comCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comOmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comOmniAb price target lowered to $4 from $7 at RBC CapitalMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTM, EGHT, OABI, and AHG Company DescriptionsAkso Health Group NASDAQ:AHG$1.25 +0.03 (+2.03%) Closing price 06/27/2025 03:58 PM EasternExtended Trading$1.24 -0.02 (-1.59%) As of 06/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. It also offers consultancy and information technology support services; provides health treatment services; sells medical devices; and trades in branded products, as well as promotes products. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.Castellum NYSEAMERICAN:CTM$1.06 0.00 (0.00%) Closing price 06/27/2025 04:10 PM EasternExtended Trading$1.04 -0.02 (-1.79%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castellum, Inc. provides services in the areas of cybersecurity, information technology, electronic and information warfare, and information operations. Its services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model based systems engineering services. It serves customers in the federal government, financial services, healthcare, and other data application sectors. The company is based in Bethesda, Maryland.8X8 NASDAQ:EGHT$1.86 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.81 -0.05 (-2.69%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.8x8, Inc. engages in the provision of enterprise communication solutions. It offers solutions to the business services, education, financial services, government, healthcare, and manufacturing industries. The company was founded in February 1987 and is headquartered in Campbell, CA.OmniAb NASDAQ:OABI$1.70 +0.01 (+0.59%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
